GeneDx announced a monumental accomplishment in its ongoing commitment to deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company has successfully sequenced more than 500,000 clinical exomes, solidifying its place as an industry leader in exome sequencing, enhancing the robustness of its proprietary dataset in order to enable more definitive diagnoses for more patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WGS:
- GeneDx announces data on whole exome, genome sequencing report fewer VUS
- GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
- GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GeneDx reports Q2 EPS ($1.84), consensus ($1.31)
- PacBio and GeneDx announce research collaboration with University of Washington